Gene study boosts hopes for Merck's Zetia; Sun profits lag estimates; Stada buyout gains offset sliding Russia sales;

human heart

@FiercePharma: Merck JV signs on Bangladeshi firms to speed low-cost cholera candidate. More | Follow @FiercePharma

@EricPFierce: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. Story | Follow @EricPFierce

@CarlyHFierce: At long last, Sanofi launches low-cost pentavalent in India. More | Follow @CarlyHFierce

> A new U.S. genetic study that connects a particular mutation to lowered heart risk raised hopes for Merck's ($MRK) cholesterol drug Zetia, which acts on the same gene. Report

> India's Sun Pharmaceuticals saw quarterly profits rise 15%, but the $255 million in net profits still lagged estimates. Report

> Germany's Stada reported a 12% hike in core earnings, thanks to gains on the takeover of British consumer care company Thornton & Ross, which offset sliding sales in Russia. Report

> Sanofi's ($SNY) decision to team up with Unilife on a supply of wearable injectors could eventually push the drug-delivery company's sales by up to $1 billion annually. Report

Medical Device News

@FierceMedDev: Medtronic borrows $16B to cover rising costs of Covidien deal. More | Follow @FierceMedDev

@VarunSaxena2: Xerox invests in HealthSpot, a telemedicine provider. More | Follow @VarunSaxena2

@EmilyWFierce: First pharma swag submission of the day: Flonase wristwatch. Feel free to send pics to [email protected]Picture | Follow @EmilyWFierce

> Congressional Republicans move full speed ahead to nix medical device tax. Story

> Glooko merges tech data to avoid activity-triggered hypoglycemic events. Article

> Consultant says Sunshine Act leads to implicit coordination of payments to docs. Article

Biotech News

@FierceBiotech: AstraZeneca trumpets a preclinical long shot in bid to burnish Brilinta's prospects. More | Follow @FierceBiotech

@JohnCFierce: Oxigene's positive PhII ovarian cancer data faces analyst's skepticism. More | Follow @JohnCFierce

@DamianFierce: Top-notch brand synergy here. Nothing says "trustworthy" like a pawnbroker. Picture | Follow @DamianFierce

> Snap studies will test antivirals from Chimerix, Fujifilm as a remedy for Ebola. Story

> PRA joins the CRO in-crowd with a $306M IPO. Report

> Sanofi execs prep their pitch on a post-Viehbacher R&D strategy. Article

Vaccines News

> Report: Sanofi has billion-dollar dengue opportunity in India. Item

> U.K. pols press PM Cameron on Bexsero coverage delay. Story

> Study: Universal E. coli vaccine appears possible thanks to limited number of strains. Report

> At long last, Sanofi launches low-cost pentavalent in India. More

> Merck JV signs on Bangladeshi firms to speed low-cost cholera candidate. Story

> Dendreon bankruptcy weighs on cancer vaccine field. Article

Pharma Manufacturing News

> Consort's Aesica buyout sets it up to jointly develop drugs and delivery devices. Story

> Sun's deal to buy Ranbaxy faces delays. Article

> Spain's Exeltis gets two plants in Turkey with deal for Embil. More

> Neopharma to build plant in Saudi Arabia. Story

> Police probe wholesalers for selling subsidized drugs outside of Spain. Article

And Finally... Former SAC trader Matthew Martoma, sentenced for prison in an insider trading scheme centered on drug development, failed to persuade a judge to allow him to remain out of jail until his appeal can be heard. Report